QuidelOrtho Corporation (NASDAQ:QDEL) Stock Now Rated "Reduce" by Sell-Side Analysts

Key Points

• QuidelOrtho received an average “Reduce” rating from six analysts, with three sell ratings and three holds. The average 12-month price target is $13.62.
• The company beat quarterly expectations, reporting $0.13 EPS versus a projected $0.05 loss and $630.9 million in revenue, up 2.8% year over year. Management issued fiscal 2026 EPS guidance of $0.65–$0.90.
• QDEL opened at $13.42, near its 52-week low of $9.92 and well below its high of $35.58; institutional investors and hedge funds own approximately 99% of the stock.

Shares of QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) have been given an average rating of "Reduce" by the six ratings firms that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell rating and three have issued a hold rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $13.62.

Several research firms have recently issued reports on QDEL. Zacks Research lowered shares of QuidelOrtho from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 12th. Weiss Ratings restated a "sell (e+)" rating on shares of QuidelOrtho in a research note on Friday, July 17th. JPMorgan Chase & Co. lifted their price target on QuidelOrtho from $11.00 to $12.00 and gave the company an "underweight" rating in a research note on Wednesday, July 1st. Jefferies Financial Group reaffirmed a "hold" rating on shares of QuidelOrtho in a report on Monday, June 29th. Finally, Citigroup increased their price target on QuidelOrtho from $13.00 to $18.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 8th.

QuidelOrtho Stock Performance

QDEL opened at $13.42 on Monday. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The firm has a fifty day moving average price of $13.14 and a 200 day moving average price of $13.98. QuidelOrtho has a 1 year low of $9.92 and a 1 year high of $35.58. The stock has a market cap of $920.21 million, a P/E ratio of -0.87 and a beta of 0.79.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The company had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. During the same quarter last year, the business earned $0.12 earnings per share. The firm's revenue was up 2.8% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Equities research analysts anticipate that QuidelOrtho will post 0.75 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in QDEL. Integrated Wealth Concepts LLC purchased a new position in QuidelOrtho in the 2nd quarter valued at about $53,000. IFP Advisors Inc boosted its holdings in QuidelOrtho by 14,166.7% in the 2nd quarter. IFP Advisors Inc now owns 2,568 shares of the company's stock worth $45,000 after buying an additional 2,550 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in QuidelOrtho during the 2nd quarter worth approximately $1,493,000. Allworth Financial LP increased its stake in QuidelOrtho by 161.3% during the 2nd quarter. Allworth Financial LP now owns 3,209 shares of the company's stock worth $56,000 after buying an additional 1,981 shares in the last quarter. Finally, Corient Private Wealth LP acquired a new position in shares of QuidelOrtho during the second quarter valued at approximately $363,000. 99.00% of the stock is owned by institutional investors and hedge funds.

About QuidelOrtho

QuidelOrtho Corporation NASDAQ: QDEL develops, manufactures and distributes diagnostic products used by healthcare providers, clinical laboratories and blood-processing organizations. The company's offerings are designed to support the detection, diagnosis and monitoring of infectious diseases, cardiovascular conditions and other medical conditions.

Its product portfolio includes point-of-care testing systems, molecular diagnostic assays, immunoassays, clinical chemistry and immunodiagnostic platforms, as well as transfusion medicine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.